{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:21:28Z","timestamp":1783938088195,"version":"3.55.0"},"reference-count":81,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":937,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors, along with BRAF and MEK inhibitors, have dramatically changed the management of and outlook for patients with metastatic melanoma. Analyses of long-term follow-up data and subanalyses based on disease characteristics may inform clinical decision making.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Reports of clinical trials in metastatic melanoma published between January 1, 2012, and August 30, 2018, were identified using PubMed (terms: melanoma AND [dabrafenib OR trametinib OR vemurafenib OR cobimetinib OR encorafenib OR ipilimumab OR nivolumab OR pembrolizumab]) and were systematically reviewed. Relevant congress proceedings were also assessed. Efficacy data from key phase III trials were analyzed and trends identified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Substantial improvements in objective response rates, progression-free survival, and overall survival were documented across 14 identified publications. Subgroup findings supported that patients with lower disease burden derive greater benefit than patients with more advanced disease, limiting the value of disease burden in the clinical decision-making process. However, these agents consistently conferred benefits despite the presence of poor prognostic features. Several clinically relevant questions remain, including how best to sequence immune checkpoint inhibitors and combination targeted therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This research, coupled with ongoing investigations, including those on predictive biomarkers, suggests that the treatment decision-making process is likely to become more nuanced.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>The management of melanoma has been rapidly advancing with new classes of agents, including immune checkpoint and BRAF inhibitors. With long-term follow-up, their impact on response rates and survival outcomes is well documented. Additional findings from subgroup analyses suggest that patients with lower disease burden derive greater benefit, yet both consistently confer benefit in patients with higher disease burden. Currently, there is a paucity of data to guide first-line treatment selection between immunotherapy and BRAF-targeted therapy in clinical practice or to estimate their impact when sequenced. Gaining these insights will facilitate a more nuanced management approach.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0876","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T18:55:44Z","timestamp":1557255344000},"page":"e1197-e1211","source":"Crossref","is-referenced-by-count":16,"title":["Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma"],"prefix":"10.1093","volume":"24","author":[{"given":"Jason J.","family":"Luke","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, University of Chicago Comprehensive Cancer Center, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"issue":"8","key":"2021122508042105500_onco12954-bib-0001","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: Optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122508042105500_onco12954-bib-0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","article-title":"Systematic review of medical treatment in melanoma: Current status and future prospects","volume":"16","author":"Garbe","year":"2011","journal-title":"The Oncologist"},{"key":"2021122508042105500_onco12954-bib-0003","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122508042105500_onco12954-bib-0004","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): A multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"2021122508042105500_onco12954-bib-0005","first-page":"1215OA","article-title":"Results of COLUMBUS part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma","volume":"28","author":"Dummer","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122508042105500_onco12954-bib-0006","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): A multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122508042105500_onco12954-bib-0007","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1158\/1078-0432.CCR-15-2709","article-title":"Talimogene laherparepvec for the treatment of advanced melanoma","volume":"22","author":"Ott","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122508042105500_onco12954-bib-0008","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122508042105500_onco12954-bib-0009","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122508042105500_onco12954-bib-0010","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2014.13943","article-title":"Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial","volume":"312","author":"Hodi","year":"2014","journal-title":"JAMA"},{"key":"2021122508042105500_onco12954-bib-0011","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122508042105500_onco12954-bib-0012","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508042105500_onco12954-bib-0013","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122508042105500_onco12954-bib-0014","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508042105500_onco12954-bib-0015","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508042105500_onco12954-bib-0016","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508042105500_onco12954-bib-0017","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","article-title":"Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma","volume":"86","author":"Hamid","year":"2017","journal-title":"Eur J Cancer"},{"key":"2021122508042105500_onco12954-bib-0018","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122508042105500_onco12954-bib-0019","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122508042105500_onco12954-bib-0020","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122508042105500_onco12954-bib-0021","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"2021122508042105500_onco12954-bib-0022","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","article-title":"Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma","volume":"31","author":"Ascierto","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122508042105500_onco12954-bib-0023","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122508042105500_onco12954-bib-0024","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the MEK1\/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122508042105500_onco12954-bib-0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508042105500_onco12954-bib-0026","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122508042105500_onco12954-bib-0027","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamaoncol.2016.0509","article-title":"Clinical, molecular, and immune analysis of dabrafenib-trametinib combination treatment for BRAF inhibitor-refractory metastatic melanoma: A phase 2 clinical trial","volume":"2","author":"Chen","year":"2016","journal-title":"JAMA Oncol"},{"key":"2021122508042105500_onco12954-bib-0028","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(17)30171-7","article-title":"Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: An open-label, single arm, dual-centre, phase 2 clinical trial","volume":"18","author":"Schreuer","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122508042105500_onco12954-bib-0029","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122508042105500_onco12954-bib-0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021122508042105500_onco12954-bib-0031","author":"Weber","year":"2016"},{"issue":"suppl 15","key":"2021122508042105500_onco12954-bib-0032","doi-asserted-by":"crossref","first-page":"9505A","DOI":"10.1200\/JCO.2016.34.15_suppl.9505","article-title":"Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)","volume":"34","author":"Wolchok","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122508042105500_onco12954-bib-0033","author":"Larkin","year":"2017"},{"key":"2021122508042105500_onco12954-bib-0034","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122508042105500_onco12954-bib-0035","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"2021122508042105500_onco12954-bib-0036","first-page":"1222PDA","article-title":"Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)","volume":"28","author":"Grob","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"2021122508042105500_onco12954-bib-0037","doi-asserted-by":"crossref","first-page":"9504A","DOI":"10.1200\/JCO.2016.34.15_suppl.9504","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006","volume":"34","author":"Schachter","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021122508042105500_onco12954-bib-0038","doi-asserted-by":"crossref","first-page":"9503A","DOI":"10.1200\/JCO.2018.36.15_suppl.9503","article-title":"4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006","volume":"36","author":"Long","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122508042105500_onco12954-bib-0039","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: Final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122508042105500_onco12954-bib-0040","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl 15","key":"2021122508042105500_onco12954-bib-0041","doi-asserted-by":"crossref","first-page":"9522A","DOI":"10.1200\/JCO.2018.36.15_suppl.9522","article-title":"Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive metastatic melanoma: Analysis from the 4-year extended follow-up of the phase 3 coBRIM study","volume":"36","author":"Dr\u00e9no","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021122508042105500_onco12954-bib-0042","doi-asserted-by":"crossref","first-page":"9526A","DOI":"10.1200\/JCO.2017.35.15_suppl.9526","article-title":"Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600-mutant melanoma","volume":"35","author":"Chapman","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122508042105500_onco12954-bib-0043","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.12.015","article-title":"Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E\/K-mutant advanced or metastatic melanoma","volume":"109","author":"Robert","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6","key":"2021122508042105500_onco12954-bib-0044","first-page":"LBA40A","article-title":"Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E\/k-mutant cutaneous melanoma","volume":"27","author":"Robert","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122508042105500_onco12954-bib-0045","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"2021122508042105500_onco12954-bib-0046","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/k-mutant melanoma: Long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122508042105500_onco12954-bib-0047","doi-asserted-by":"crossref","first-page":"9504A","DOI":"10.1200\/JCO.2018.36.15_suppl.9504","article-title":"Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma","volume":"36","author":"Dummer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122508042105500_onco12954-bib-0048","author":"Dummer","year":"2016"},{"key":"2021122508042105500_onco12954-bib-0049","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: A pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122508042105500_onco12954-bib-0050","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"2021122508042105500_onco12954-bib-0051","doi-asserted-by":"crossref","first-page":"3068A","DOI":"10.1200\/jco.2015.33.15_suppl.3068","article-title":"Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma","volume":"33","author":"Joseph","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122508042105500_onco12954-bib-0052","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/cncr.28620","article-title":"Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors","volume":"120","author":"Ackerman","year":"2014","journal-title":"Cancer"},{"key":"2021122508042105500_onco12954-bib-0053","doi-asserted-by":"crossref","first-page":"djv414","DOI":"10.1093\/jnci\/djv414","article-title":"Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: Current perspectives","volume":"108","author":"Atkins","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2021122508042105500_onco12954-bib-0054","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.31889","article-title":"Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy","volume":"125","author":"Saab","year":"2019","journal-title":"Cancer"},{"key":"2021122508042105500_onco12954-bib-0055","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-17-0401","article-title":"Recurrent tumor cell-intrinsic and -extrinsic alterations during MAPKi-induced melanoma regression and early adaptation","volume":"7","author":"Song","year":"2017","journal-title":"Cancer Discov"},{"key":"2021122508042105500_onco12954-bib-0056","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur J Cancer"},{"key":"2021122508042105500_onco12954-bib-0057","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"2021122508042105500_onco12954-bib-0058","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"key":"2021122508042105500_onco12954-bib-0059","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): An open-label, randomised, phase 2 trial","volume":"17","author":"Weber","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122508042105500_onco12954-bib-0060","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-12-3080","article-title":"Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control","volume":"19","author":"Robert","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2021122508042105500_onco12954-bib-0061","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): A multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"issue":"suppl 15","key":"2021122508042105500_onco12954-bib-0062","doi-asserted-by":"crossref","first-page":"9507A","DOI":"10.1200\/JCO.2017.35.15_suppl.9507","article-title":"Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204","volume":"35","author":"Tawbi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021122508042105500_onco12954-bib-0063","doi-asserted-by":"crossref","first-page":"9508A","DOI":"10.1200\/JCO.2017.35.15_suppl.9508","article-title":"A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC)","volume":"35","author":"Long","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122508042105500_onco12954-bib-0064","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021122508042105500_onco12954-bib-0065","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11060-015-1881-3","article-title":"Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases","volume":"125","author":"Kohutek","year":"2015","journal-title":"J Neurooncol"},{"key":"2021122508042105500_onco12954-bib-0066","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1470-2045(18)30187-6","article-title":"Changing the standard of care for treating melanoma brain metastases","volume":"19","author":"Chapman","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021122508042105500_onco12954-bib-0067","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"2021122508042105500_onco12954-bib-0068","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122508042105500_onco12954-bib-0069","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and immune evolution of melanoma acquiring MAPKi resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"key":"2021122508042105500_onco12954-bib-0070","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/1078-0432.CCR-13-1081","article-title":"Molecular pathways: Adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer","volume":"20","author":"Johnson","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021122508042105500_onco12954-bib-0071","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122508042105500_onco12954-bib-0072","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122508042105500_onco12954-bib-0073","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122508042105500_onco12954-bib-0074","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med."},{"key":"2021122508042105500_onco12954-bib-0075","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122508042105500_onco12954-bib-0076","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","article-title":"Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study","volume":"50","author":"Dummer","year":"2014","journal-title":"Eur J Cancer"},{"key":"2021122508042105500_onco12954-bib-0077","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdw641","article-title":"Vemurafenib in metastatic melanoma patients with brain metastases: An open-label, single-arm, phase 2, multicentre study","volume":"28","author":"McArthur","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122508042105500_onco12954-bib-0078","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122508042105500_onco12954-bib-0079","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib","volume":"36","author":"Long","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122508042105500_onco12954-bib-0080","first-page":"997A","article-title":"Overall survival (OS) update on METRIC (NCT01245062), a randomized phase 3 study to assess efficacy of trametinib (T) compared with chemotherapy (C) in patients (pts) with BRAFV600E\/K mutation-positive (+) advanced or metastatic melanoma (MM)","volume":"26","author":"Schadendorf","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"2021122508042105500_onco12954-bib-0081","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0876","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0876","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/e1197\/41917849\/oncolo_24_11_e1197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/e1197\/41917849\/oncolo_24_11_e1197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:05:49Z","timestamp":1640419549000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/11\/e1197\/6439939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":81,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,5,7]]},"published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0876","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,1]]},"published":{"date-parts":[[2019,5,7]]}}}